Genetic and microenvironmental implications in prostate cancer progression and metastasis

European Review for Medical and Pharmacological Sciences

Volumn 12, Issue 3, 2008, Pages 167-175

  Alberti, Contardo ^a  

^a UNIVERSITY OF PARMA   (Italy)

Author keywords

Inflammation; Metastatic genes; Microenvironment; Prostate carcinoma; Tumor progression

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CANCER VACCINE; CYCLOOXYGENASE 2; CYTOKINE; DIPHENYLIODONIUM SALT; GAMBOGIC ACID; GROWTH FACTOR; NITROGEN; ONCOPROTEIN; OXYGEN; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN DAN1; PROTEIN FAT; PROTEIN MTA1; PROTEIN MYBL2; PROTEIN RAB5A; SMALL INTERFERING RNA; SOMATOMEDIN BINDING PROTEIN; SORAFENIB; SUNITINIB;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER STEM CELL; CHROMOSOME ABERRATION; CYTOGENETICS; DEACETYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENOMICS; HUMAN; MACROPHAGE; MALE; METASTASIS; METASTASIS POTENTIAL; MICROENVIRONMENT; NEUTROPHIL; NONHUMAN; ONCOGENE; PLEIOTROPY; PROSTATE CANCER; PROSTATE CARCINOMA; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE; UPREGULATION;

DISEASE PROGRESSION; HUMANS; INFLAMMATION; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 48149091949     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (87)

1. JEMAL A, SIEGEL R, WARD E, HAO Y, Xu J, MURRAY T, THUN MJ. Cancer statistics 2008. CA Cancer J Clin 2008; 58: 71-76.
2. NGUYEN DX, MASSEGUÈ J. Genetic determinants of cancer metastasis. Nature Rev Genet 2007; 8: 341-352.
3. CRESPI B, SUMMERS K. Evolutionary biology of cancer. Trends Ecol Evol 2005; 20: 545-552.
4. YOSHIMOTO M, CUNHA IW, COUDRY RA, FONSECA FP, TORRES CH, SOARES FA, SOUIRE JA. FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer 2007; 97: 678-685.
5. RIBEIRO FR, HENRIOUE R, HEKTOEN M, BERG M, JERÓNIMO C, TEIXEIRA MR, LOTHE RA. Comparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas. Mol Cancer 2006b; 5: 33.
6. SCHMITZ M, GRIGNARD G, MARGUE C, DIPPEL W. CAPESIUS C, MOSSONG J, NATHAN M, GIACCHI S, SCHEIDEN R, KIEFFER N. Complete loss of PTEN expression as a possible early prognostic marker for prostate cancer metastasis. Int J Cancer 2007; 120: 1284-1292.
7. TAHIR SA, YANG G, GOLTSOV AA, WATANABE M, TABATA K, ADDAI J, FATTAH EL MA, KADMON D, THOMPSON TC. Tumor cell-secreted caveolin-1 has proangiogenic activities in prostate cancer. Cancer Res 2008; 68:731-739.
8. WOODSON K, GILLESPIE J, HANSON J, EMMERT-BUCK M, PHILLIPS JM, LINEHAN WM, TANGREA JA. Heterogeneous gene methylation patterns among pre-invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimens. Prostate 2004; 60: 25-31.
9. CHUNG LW, BASEMAN A, ASSIKIS V, ZHAU HE. Molecular insight into prostate cancer progression: The missing link of tumor microenvironment. J Urol 2005; 66:671-675.
10. KAPLAN RN, RAFIL S, LYDEN D. Preparing the "soil", The premetastatic niche. Cancer Res 2006; 66: 11089-11093.
11. GUPTA GP, MASSAGUÉ J. Cancer metastasis: Building a framework. Cell 2005; 127: 679-695.
12. MINN AJ, GUPTA GP, PADUA D, BOS P, NGUYEN DX, NUYTEN D, KREIKE B, ZHANG Y, WANG Y, ISHWARAN H, FOEKENS JA, VAN DE VUVER M, MASSAGUÉ J. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007; 104: 6740-6745.
13. GUPTA GP, NGUYEN DX, CHIANG AC, BOS PD, KIM JY, NADAL C, GOMIS RR, MANOVA-TODOROVA K, MASSAGUÉ J. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007; 446: 765-770.
14. BLANSFIELD JA, CARAGACIANU D, ALEXANDER HR 3RD, TANGREA MA, MORITA SY, LORANG D, SCHAFER P, MULLER G, STIRLING D, ROYAL RE, LIBUTTI SK. Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. Clin Cancer Res 2008; 14: 270-280.
15. GERALD WL. Genome-wide gene expression analysis of prostate carcinoma. Sem Oncol 2003; 30: 635-648.
16. BAYLIN SB, OHM JE. Epigenetic gene silencing in cancer. A mechanism for early oncogenic pathway addition? Nature Rev Cancer 2006; 6, 107-116.
17. SELLERS WR, LODA M. The EZH2 polycomb transcriptional repressor: A marker or mover of metastatic prostate cancer? Cancer cell 2002; 2: 349-350.
18. WHEELOCK MI, SHINTANI Y, MAEDA M, FUKUMOTO Y, JOHNSON KR. Cadherin switching. J Cell Science 2008; 121: 727-735.
19. VELA I, GREGORY L, GARDINER EM, CLEMENTS JA, NICOL DL. Bone and prostate cancer cell interactions in metastatic prostate cancer. BJU Int 2006; 99: 735-742.
20. s in prostate cancer bone metastases. J Cell Biochem 2006; 97: 661-672.
21. REYA T, CLEVERS H. Wnt signalling in stem cells cancer. Nature 2005; 434: 843-850.
22. COLLINS A, MAITLAND NJ. Prostate cancer stem cells. Eur J Cancer 2006; 42: 1213-1218.
23. CHUNG LW, HUANG WC, SUNG SY, WU D, ODEROMARAH V, NOMURA T, SHIGEMURA K, MIYAGI T, SEO S, SHI C, MOLITIERNO J, ELMORE J, ANDERSON C, ISOTANI S, EDLUND M, HSIEH CL, WANG R, SHEHATA B, ZHAU HE. Stromal-epithelial interaction in prostate cancer progression. Clin Genitourin Cancer 2006; 5: 162-170.
24. HILL R, SONG Y, CARDIFF RD, DANDYKE T. Selective evolution of stromal mesenchime with p53 loss in response to epithelial tumorigenesis. Cell 2005; 123: 1001-1011.
25. SINGH H, DANG TG, AYALA GE, ROWLEY DR. TGF-induced myofibroblasts regulate LNCaP cell death. J Urol 2004; 172: 2421-2425.
26. KELLER ET, ZHANG J, COOPER CR, SMITH PC, MCCAULEY LK, PIENTA KJ, TAICHMAN RS. Prostate carcinoma skeletal metastases: Cross-talk between tumor and bone. Cancer Metastasis Rev 2001; 20: 339-349.
27. GUISE TA. Molecular mechanisms of osteolytic bone metastases. Cancer 2000; 88 (suppl 12); 2892-2898.
28. MUNDY GR. Metastasis to bone: Causes, consequences and therapeutic opportunities. Nature Rev Cancer 2002; 2: 584-593.
29. BRADLEY DA, HUSSAIN M, DI PAOLA RS. KANTOFF PH. Bone directed therapies for prostate cancer. J Urol 2007; 178:1515-1522.
30. WOODHOUSE EC, CHUAQUI RF, LIOTTA LA. General mechanisms of metastasis. Cancer 1997; 80 (suppl): 1529-1531.
31. VIGNUEVIC D, FRE S, LOUVARD D, ROBINE S. Conditional mouse models of cancer. Handl Exp Pharmacol 2007; 178: 263-287.
32. BROWMICK NA, MOSES HL. Tumor-stroma interactions. Curr Opin Genet Dev 2005; 15: 97-101.
33. OLSSON AK, DIMBERG A, KREUGER J, CLAESSON-WELSH L. VEGF-receptor signalling in control of vascular function. Nature Rev Mol Cell Biol 2006; 7: 359-371.
34. HARRIS AL. Hypoxia, a key regulator factor in tumor growth. Nat Rev Cancer 2002; 2: 38-47.
35. KITAGAWA Y, DAI J, ZHANG J, KELLER JM, NOR J, YAO Z, KELLER ET. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. Cancer Res 2005; 65: 10921-10929.
36. DAHUT WL, SCRIPTURE C, POSADAS E, JAIN L, GULLEY JL, ARLEN PM, WRIGHT JJ, YU Y, CAO L, STEINBERG SM, ARAGON-CHING JB, VENITZ J, JONES E, CHEN CC, FIGG WD. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14:209-215.
37. HOSTMAN A. PDGF-receptor-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma. Cytokine Growth Factor Rev 2004; 15: 275-286.
38. FUJIUCHI Y, NAGAKAWA O, MURAKAMI K, FUSE H, SAIKI I. Effect of HGF on invasion of prostate cancer cell lines. Oncol Rep 2003; 10: 1001-1006.
39. GIORDANO S, CORSO S, CONROTTO P, ARTIGIANI S, GILESTRO G, BARBERIS D, TAMAGNONE L, COMOGLIO PM. The semaphorin 4D receptor controls invasive growth of coupling with Met. Nature Cell Biol 2002; 4: 720-724.
40. GARRETT SC, VARNEY KM, WEBER DJ, BRESNICK AR. S100A4, a mediator of metastasis. J Biol Chem 2006; 281: 677-680.
41. EDLUND M, SUNG SY, CHUNG LW. Modulation of prostate cancer growth in bone microenvironments. J Cell Biochem 2004; 91: 686-705.
42. WRIGHT ME, TSAI MJ, AEBERSOLD R. Androgen receptor represses neuroendocrine transdifferentiation process in prostate cancer cells. Molec Endocrinol 2003; 17:1726-1737.
43. HUANG X, ZHANG X, FARAHVASH B, OLUMI AF. Novel targeted proapoptotic agents for the treatment of prostate cancer. J Urol 2007; 178:1846-1854.
44. CORCORAN NM, COSTELLO AJ, HOVENS CM. Interfering with cell-survival signalling as a treatment strategy for prostate cancer. BJU Int 2006; 97: 1149-1155.
45. GRANCHI S, BROCCHI S, BONACCORSI L, BALDI E, VINCI MC, FORTI G, SERIO M, MAGGI M. Endothelin-1 production by prostate cancer cell lines is up-regulated by factors involved in cancer progression and down-regulated by androgens. Prostate 2001; 49: 267-277.
46. NADIMINTY N, LOU W, LEE SO, MEHRAEIN-GHOMI F, KIRK JS, CONROY JM, ZHANG H, GAO AC. Prostate-specific antigen modulates genes involved in bone remodelling and induces osteoblast differentiation of human osteosarcoma cell line SaOS-2. Clin Cancer Res 2006; 12: 1420-1430.
47. THIERY JP. Epithelial-mesenchymal transition in tumor progression. Nat Rev Cancer 2002; 2: 442-448.
48. JACOB K, WEBBER M, BENAYAHU D, KLEINMAN AK. Osteonectin promotes prostate cancer migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453-4457.
49. LUCIA MS, TORKKO KC. Inflammation as a target for prostate cancer chemoprevention: Pathological and laboratory rationale. J Urol 2004; 171: S30-S35.
50. COUSSENS LM, WERB Z. Inflammation and cancer. Nature 2002; 420: 860-865.
51. BALKWILL F, MANTOVANI A. Inflammation and cancer: Back to Virchow? Lancet 2001; 357: 534-544.
52. KARIN M. NF-kB and cancer: Mechanisms and target. Mol Carinogenesis 2006; 45: 355-361.
53. MIZOKAMI A, GOTOH A, YAMADA H, KELLER ET, MATSUMOTO T. Tumor necrosis factor-α represses androgen-sensitivity in the LNCaP prostate cancer cell line. J Urol 2000; 164: 800-805.
54. RICHMOND A. NF-kB, chemokine gene transcription and tumour growth. Nat Rev Immunol 2002; 2: 664-670.
55. HOLD GL, EL-HOMAR EM. Genetic aspects of inflammation and cancer. Biochem J 2008; 410: 225-235.
56. CAO Y, PRESCOTT SM. Many actions of Cox-2 in cellular dynamics and in cancer. J Cell Physiol 2002; 190: 279-285.
57. PEWZNER-JUNG V, BEN-DOR S, FUTERMAN AH. When do lasses (longevity assurance genes) become Cer-S (Ceramide-synthases)? Biol Chem 2006; 281: 25001-25005.
58. GASBARRINI A, PASINI P, NARDO B, DE NOTARIIS S, SIMONCINI M, CAVALLARI A, RODA E, BERNARDI M, RODA A. Chemiluminescent real rime imaging of post-ischemic oxygen free radical formation in liver isolated from young and old rats. Free Radic Biol Med 1998; 24: 211-216.
59. PALMIERI B, SBLENDORIO V. Oxidative stress detection: What for? Eur Rev Med Pharmacol Sci 2007; 11: 27-54.
60. SHIGEMURA K, SUNG SY, KUBO H, ARNOLD RS, FUJISAWA M, GOTOH A, ZHAU HE, CHUNG LW. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 2007; 67: 722-731.
61. BALKWILL F, CHARLES KA, MANTOVANI A. Smaldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer cell 2005; 7: 211-217.
62. DE VISSER K, EICHTEN A, COUSSENS LM. Paradoxical roles of the immune system during cancer development. Nar Rev Cancer 2006; 6: 24-37.
63. KARIN M. Nuclear factor-kB in cancer development and progression. Nature 2006; 441: 431-436.
64. RADHAKRISHNAN S, LEE A, OLIVER T, CHINEGWUNDOH F. An infections cause for prostate cancer. BJU Int 2006; 99: 239-246.
65. HISADA M, RABKIN CS, STRICKLER HD, WRIGHT WE, CHRISTIANSON RE, VAN DEN BERG B.J. Human papillomavirus antibody and risk of prostate cancer. JAMA 2000; 283: 340-341.
66. HAGER M, MIKUZ G, BARTSCH G, KOLBITSCH C, MOSER PL. The association between local atherosclerosis and prostate cancer. BJU Int 2006; 99: 46-48.
67. SUTCLIFFE S, PLATZ EA. Inflammation in the aetiology of prostate cancer: An epidemiologic perspective. Urol Oncol 2007; 25: 242-249.
68. SUN J, TURNER A, XU J, GRÖNBERG H, ISAACS W. Genetic variability in inflammation pathways and prostate cancer risk. Urol Oncol 2007; 25: 250-259.
69. LICASTRO F, BERTACCINI A, PORCELLINI E, CHIAPPELLI M, PERNETTI R, SANGUEDOLCE F, MARCHIORI D, MARTORANA G. Alpha 1 antichymotrypsin genotype is associated with increased risk of prostate carcinoma and PSA levels. Anticancer Res 2008; 28: 395-400.
70. TSUJIE M, TSUJIE T, TOI H, UNEDA SH, SHIOZAKI K, TSAI H, SEON BK. Anti-tumor activity of an anti-endoglin monoclonal antybody is enhanced in immunocompetent mice. Int J Cancer 2008; 122: 2266-2273.
71. PADUA D, ZHANG X, WANG Q, NADAL C, GERALD WL, GOMIS RR, MASSAGUÉ J. TGF-beta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 2008; 133: 66-77.
72. CHUNG LW. Prostate carcinoma bone-stroma interaction and its biological and therapeutic implications. Cancer 2003; 97: 772-778.
73. YI T, YI Z, CHO SG, LUO J, PANDEY MK, AGGARWAL BB, LIU M. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008; 68: 1843-1850.
74. KUMAR B, KOUL S, KHANDRIKA L, MEACHAM RB, KOUL HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785.
75. SCHAMHART DHT, WESTERHOF ACC. Strategies for gene cloning. Urol Res 1999; 27: 83-96.
76. SCHALKEN J, VISAKORPI T, THALMANN G, VAN DEL POEL H. Molecular biology for Urologists. Eur Urol 2001; 39/4 (Curric Urol): 1-11.
77. ARMSTRONG A, FEBBO PG, GEORGE DJ, MOUL J. Systemic strategies for prostate cancer. Minerva Urol Nephrol 2007; 59: 11-25.
78. VALERI A, CORMIER L., MOINEAU MP, CANCEL-TASSIN G, AZZOUZI R, DOUCET L, BASCHET F, CUSSENOT I, L'HER J, BERTHON P, MANGIN P, CUSSENOT O, MORIN JF, FOURNIER G. Targeted screening for prostate cancer in high risk families: Early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168: 483-487.
79. DE FOUGEROLLES A, VORNLOCHER HP, MARAGANORE J, LIEBNERMAN J. Interfering with disease: A progress report an siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453.
80. DOBOSY JR, ROBERTS JLW, FU VX, JARRARD DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007; 177: 822-831.
81. LERNER I, BARAZ L, PIKARSKY E, MEIROVITZ A, EDOVITSKY E, PERETZ T, VLODAVSKY J, ELKIN M. Function of heparanase in prostate tumorigenesis: Potential for therapy. Clin Cancer Res 2008; 14: 668-676.
82. MIYAKE H, HARA I, FUJIAMA M, GLEAVE ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Invest Drugs 2006; 15: 507-517.
83. EDER IE, BEKTIC J, HAAG P, BARTSCH G, KLOCKER H. Genes differentially expressed in prostate cancer. BJU Int 2004; 93: 1151-1155.
84. MCCABE CD, SPYROPOULOS DD, MARTIN D, MORENO CS. Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer. Cancer Res 2008; 68: 1988-1996.
85. BANGMA CH, MONGIAT P, KRAAU R, SCHENK-BRAAT E. Gene therapy in urology: Strategies to translate theory into practice. BJU Int. 2005; 96: 1163-1170.
86. GARCIA-HERNANDEZ M, GRAY A, HUBBY R, KUNGER OJ, Kast M. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008; 68; 861-869.
87. MARIGO I, DOLCETTI L, SERAFINI P, ZANOVELLO P, BRONTE V. Tumor-induced tolerance and immune suppression by myeloid-derived suppressor cells. Tumor Immunol 2008; 222: 162-179.